Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CHAT | P28329 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625481 | 0.77 | TSHR (0.40) | KDM1AFBP1ALDH1A1TSHRAKR1C3 | |
| SCHEMBL6067750 | 0.72 | GRIN2D (0.45) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9508726 | 0.71 | ALDH1A1 (0.39) | KDM1AFBP1ALDH1A1TSHRAKR1C3 | |
| SCHEMBL1377680 | 0.71 | ALDH1A1 (0.48) | MCL1FBP1ALDH1A1TSHRAKR1C3 | |
| SCHEMBL7044923 | 0.71 | MCL1 (0.48) | MCL1KDM1AFBP1ALDH1A1TSHR | |
| SCHEMBL16432781 | 0.71 | MCL1 (0.48) | MCL1KDM1AFBP1ALDH1A1TSHR | |
| SCHEMBL236283 | 0.71 | MCL1 (0.48) | MCL1KDM1AFBP1ALDH1A1TSHR | |
| SCHEMBL859579 | 0.71 | MCL1 (0.48) | MCL1KDM1AFBP1ALDH1A1TSHR | |
| SCHEMBL16432779 | 0.71 | MCL1 (0.48) | MCL1KDM1AFBP1ALDH1A1TSHR | |
| SCHEMBL3635422 | 0.70 | MEN1 (0.39) | MCL1FBP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| US-20230190796-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | JUNO THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | claimed |
| EP-3607319-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | Juno Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | claimed |
| CN-110730908-A | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified forms thereof and related methods | 朱诺治疗学股份有限公司 | 2020-01-24 | — | — | CN | claimed |
| WO-2018187791-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | JUNO THERAPEUTICS, INC (US) | 2018-10-11 | — | — | WO | claimed |
| EP-1019722-B1 | POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | claimed |
| EP-1019722-A1 | POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT | Abbott Laboratories (US) | 2000-07-19 | — | — | EP | claimed |
| US-5834230-A | Viscosity Probe | MCGILL UNIVERSITY (CA) | 1998-11-10 | — | — | US | claimed |
| WO-1997028447-A1 | POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT | ABBOTT LABORATORIES (US) | 1997-08-07 | — | — | WO | claimed |
| EP-4419206-B1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (ES) | 2025-09-17 | — | — | EP | disclosed |
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2024-12-19 | — | — | US | disclosed |
| US-12104214-B2 | PSMA-based molecular-genetic reporter system | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4419206-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundacio Institut de Bioenginyeria de Catalunya (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-5840859-A | (Aminostyryl)pyridinium compounds for radiolabelling cell membranes | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| US-5834230-A | Viscosity Probe | MCGILL UNIVERSITY (CA) | 1998-11-10 | — | — | US | disclosed |
| US-5834230-A | Viscosity Probe | MCGILL UNIVERSITY (CA) | 1998-11-10 | — | — | US | disclosed |
| WO-1997028447-A1 | POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT | ABBOTT LABORATORIES (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028447-A1 | POLYMERIC FLUOROPHORES ENHANCED BY MOIETIES PROVIDING A HYDROPHOBIC AND CONFORMATIONALLY RESTRICTIVE MICROENVIRONMENT | ABBOTT LABORATORIES (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997002246-A1 | (AMINOSTYRYL)PYRIDINIUM COMPOUNDS FOR RADIOLABELLING CELL MEMBRANES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | ABAT, GLS2, CPS1 | MCL1 1105/4885KDM1A 3978/4885FBP1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.